https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-12-08 / Genet. Mol. Res. 2015 Dec;14(4):16222-32
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-12-08 / Genet. Mol. Res. 2015 Dec;14(4):16222-322015-12-08 00:00:002015-12-08 00:00:00Clinical research on dendritic cell vaccines to prevent postoperative recurrence and metastasis of liver cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-11-05 / Cancer 2016 Feb;122(3):367-77
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-11-05 / Cancer 2016 Feb;122(3):367-772015-11-05 00:00:002015-11-05 00:00:00Immunotherapy in hepatocellular carcinoma: Primed to make a difference?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-10-01 / Drug Discov Ther 2015 Oct;9(5):363-71
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-10-01 / Drug Discov Ther 2015 Oct;9(5):363-712015-10-01 00:00:002015-10-01 00:00:00Immunotherapy for hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-08-24 / Technol. Cancer Res. Treat. 2016 10;15(5):NP83-94
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-08-24 / Technol. Cancer Res. Treat. 2016 10;15(5):NP83-942015-08-24 00:00:002019-02-15 09:13:32Recombinant Newcastle Disease Virus Encoding IL-12 and/or IL-2 as Potential Candidate for Hepatoma Carcinoma Therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-07-21 / J Immunother Cancer 2015;3:32
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-07-21 / J Immunother Cancer 2015;3:322015-07-21 00:00:002019-02-15 08:47:50Route of antigen delivery impacts the immunostimulatory activity of dendritic cell-based vaccines for hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-12-11 / Hepat Oncol 2014 Oct;1(4):433-446
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-12-11 / Hepat Oncol 2014 Oct;1(4):433-4462014-12-11 00:00:002014-12-11 00:00:00Immunotherapy of hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-08-15 / J. Natl. Cancer Inst. 2014 Aug;106(8)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-08-15 / J. Natl. Cancer Inst. 2014 Aug;106(8)2014-08-15 00:00:002014-08-15 00:00:00Hyperthermia inhibits recombination repair of gemcitabine-stalled replication forks
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-07-24 / Oncol Lett 2014 Oct;8(4):1783-1787
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-07-24 / Oncol Lett 2014 Oct;8(4):1783-17872014-07-24 00:00:002019-04-03 11:16:21Sorafenib and locoregional deep electro-hyperthermia in advanced hepatocellular carcinoma: A phase II study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-01-13 / Hum Vaccin Immunother 2014;10(4):970-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-01-13 / Hum Vaccin Immunother 2014;10(4):970-62014-01-13 00:00:002014-01-13 00:00:00Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-06-24 / Technol. Cancer Res. Treat. 2014 Apr;13(2):169-75
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-06-24 / Technol. Cancer Res. Treat. 2014 Apr;13(2):169-752013-06-24 00:00:002013-06-24 00:00:00Recombinant Newcastle disease virus Anhinga strain (NDV/Anh-EGFP) for hepatoma therapy
